top of page
Pastel Gradient Background
EoSight Logo with shadow.png

Transforming Chronic Rhinosinusitis Care through Point-of-Care Diagnostics
 

Our Team.

EoSight was founded by scientists from Pharma, Academia, and Healthcare.

WonYong Lee_edited.jpg

Won-Yong Lee, DVM, PhD

CEO

Abby1to1.jpg

Abigail Pulsipher, PhD

CSO

Smith, Kristine_edited.jpg

Kristine Smith, MD, FRCSC

CMO

  • LinkedIn
  • LinkedIn
  • LinkedIn

Management

Orlandi 2026_compressed.jpg

Richard Orlandi, MD, MBA

Advisors

alignment.png

Technology

EoSwab™ and EoTracker™ are our molecular biomarker-based diagnostic technologies. 

Please check our recent peer-reviewed publications:

  • An Eosinophil Peroxidase Activity Assay Accurately Predicts Eosinophilic Chronic Rhinosinusitis: Link

  • An eosinophil peroxidase activity assay predicts acute exacerbations in post-operative CRS: Link

bottom of page